Tempus AI
Logotype for Tempus AI Inc

Tempus AI (TEM) investor relations material

Tempus AI Q3 2026 earnings summary

Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.
Logotype for Tempus AI Inc
Q3 2026 earnings summary2 Nov, 2026

Executive summary

  • Q3 revenue was $411.5M, up 23% YoY; Adjusted EBITDA reached $25.6M versus $1.5M, and net loss narrowed to $14.9M from $80.0M.

  • Gross profit increased 27% to $266.7M; growth came from Diagnostics and Data & Applications, with oncology volume up 32%.

  • Data licensing and modeling bookings exceeded $550M in 2026, including agreements with BMS and Pathos.

Financial highlights

  • Revenue was $411.5M versus $334.2M in Q3’25; gross profit was $266.7M, and non-GAAP gross profit was $271.2M.

  • Operating loss was $56.9M versus $61.0M; non-GAAP operating income was $14.4M versus an $8.7M loss.

  • GAAP net loss was $14.9M versus $80.0M; non-GAAP net income was $13.4M, or $0.07 per diluted share.

  • Cash and marketable securities totaled $854.4M at quarter-end.

Outlook and guidance

  • 2026 revenue guidance increased to $1.60B–$1.605B, representing ~25% YoY growth; Adjusted EBITDA expectation remained ~$65M.

  • Q4 revenue guidance was $458M–$463M, with continued oncology, improving hereditary, and ~30% Data & Applications growth versus Q4’25.

  • Three-year top-line growth outlook was ~25%; investment is planned alongside meaningful Adjusted EBITDA and positive cash flow.

  • xT pricing is expected to add $80M of oncology ASP benefit in 2027; xT and xF could add ~$750 of incremental ASP over several years, subject to approval.

Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.
Research faster. Power your platform.

Next Tempus AI earnings date

Logotype for Tempus AI Inc
Q4 202623 Feb, 2027
Tempus AI
Cover every name on your watchlist this earnings season.
Automations, AI chat, and live calls across 16,000+ companies.
Book demo

Next Tempus AI earnings date

Logotype for Tempus AI Inc
Q4 202623 Feb, 2027

AI chat

Ask anything. Verify everything.

Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn more

Automations

Zero in on what matters

Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more

Live audio & transcripts

Be first

Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more

Quartr MCP connects your AI environment to 17K+ public companies

Pull live transcripts, filings, and slides into Claude or Codex via MCP. Combine Quartr's global IR data with any other dataset. Run agentic research and monitoring.
Included with Quartr Pro at no extra cost.Learn more

Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.

Jamie Ross

Investment Manager, GAM Investments

GAM
GAM

Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.

Tom O'Hara

Investment Director

Ciena
Ciena

Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.

Gregg Lampf

VP of Investor Relations

Frequently asked questions

Tempus AI Inc. is a technology company that focuses on advancing precision medicine through the use of artificial intelligence, including generative AI. The company offers a suite of products aimed at improving patient care by enabling physicians to make data-driven decisions in near real-time. Tempus leverages one of the world's largest libraries of clinical and molecular data, combined with an operating system that makes this data accessible and actionable. Its tools and platforms support the discovery, development, and delivery of personalized treatments by providing insights that are continuously enhanced as more data is gathered. The company is headquartered in Chicago, Illinois, and its shares are listed on the NASDAQ.